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Retinoid therapy transformed response and survival outcomes in acutepromyelocytic leukemia (APL) but has demonstrated only modestactivity in non-APL forms of acute myeloid leukemia (AML). The
presence of natural retinoids in vivo could influence the efficacy of pharma-
cologic agonists and antagonists. We found that natural RXRA ligands, but
not RARA ligands, were present in murine MLL-AF9-derived myelomono-
cytic leukemias in vivo and that the concurrent presence of receptors and lig-
ands acted as tumor suppressors. Pharmacologic retinoid responses could be
optimized by concurrent targeting of RXR ligands (e.g., bexarotene) and
RARA ligands (e.g., all-trans retinoic acid), which induced either leukemic
maturation or apoptosis depending on cell culture conditions. Co-repressor
release from the RARA:RXRA heterodimer occurred with RARA activation,
but not RXRA activation, providing an explanation for the combination syn-
ergy. Combination synergy could be replicated in additional, but not all,
AML cell lines and primary samples, and was associated with improved sur-
vival in vivo, although tolerability of bexarotene administration in mice
remained an issue. These data provide insight into the basal presence of nat-
ural retinoids in leukemias in vivo and a potential strategy for clinical retinoid
combination regimens in leukemias beyond APL.  
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ABSTRACT
Introduction
The retinoic acid receptors (RAR) and retinoid X receptors (RXR) are ligand-acti-
vated transcription factors that influence hematopoietic stem cell self-renewal and
differentiation.1-3 Transcriptional activation of the retinoid receptors is ligand
dependent.4 Therefore, the potential activity of retinoid receptors in leukemogene-
sis may be altered depending on the availability of natural ligands within a leukemic
population, and retinoid receptors might act as either tumor suppressors or onco-
genes depending on the ligand context. However, in leukemia, it is not known
whether these receptors are exposed to natural activating ligands in vivo, or whether
different forms of leukemia might contain different quantities of functional ligands. 
There are three different RAR and RXR isoforms (α, β, and γ) that are differently
expressed in hematopoietic cells.5,6 RARA and RXRA expression are dynamically
regulated during myeloid maturation, with highest mRNA expression in mature
neutrophils.7 RAR function as obligate heterodimers with RXR, whereas RXR can
form either homodimers or heterodimers with other orphan nuclear receptors (e.g.,
peroxisome proliferator-activated receptors [PPAR], liver X receptors [LXR], etc.).4
RAR-RXR dimers bind DNA with high affinity at specific retinoic acid response ele-
ments (RARE) in target gene promoters/enhancers.8 RAR-RXR acts as a transcrip-
tional repressor by binding co-repressor complexes composed by nuclear receptor
co-repressor (N-CoR) and the silencing mediator for
retinoid and thyroid hormone receptors (SMRT) and
recruiting histone deacetylases (HDAC). Local histone
deacetylation then facilitates chromatin condensation and
gene silencing. Ligand binding alters the heterodimer con-
formation, displacing the co-repressors and facilitating
binding of co-activator complexes composed by p160
family (TIF-2/SRC-1/RAC3) with histone acetylase activi-
ty (HAT). Local histone acetylation then facilitates chro-
matin decondensation and gene transcription activation.9,10
All-trans retinoic acid (ATRA) has been proposed as the
natural ligand for RAR. Multiple natural ligands have been
proposed for RXR, including modified retinoic acids (9-cis
retinoic acid and 9-cis-13,14-dihydroretinoic acid) and
long-chain fatty acids (C22:6, C22:5; C20:4, and C24:5),
which are available in diverse tissues as well as in serum.11-15
Natural RXRA, but not RARA, ligands are present in nor-
mal hematopoietic cells in vivo under steady-state condi-
tions, with preferential distribution in myeloid cells (Gr1+)
and following myeloid stress resulting from granulocyte-
colony stimulating factor (GCSF) treatment.14
ATRA (tretinoin) has transformed the outcomes of 
M3-acute promyelocytic leukemia (APL).16,17 However,
outcomes with ATRA in non-APL AML have yielded
mixed results.18 Bexarotene is a pan-RXR-activating ligand,
which is approved for the treatment of cutaneous T-cell
lymphoma (CTCL).19 In small exploratory studies of non-
APL AML, bexarotene demonstrated evidence of activity,
but only in a small proportion of patients.20,21
We used an in vivo reporter assay to explore whether
retinoid receptors in leukemia cells are transcriptionally
active (and therefore might be best targeted with antago-
nists) or transcriptionally inactive (and therefore might be
best targeted with agonists).  Our results show that natu-
ral ligands for RXRA, but not RARA, are present at low
levels in vivo in primary mouse myelomonocytic leukemia
cells where they exhibit tumor suppressor phenotypes. 
Methods
Hematopoietic cell culture
Mouse BM Kit+ cells were isolated using an Automacs Pro
(Miltenyl Biotec, San Diego, CA, USA) and plated in RPMI 1640
medium, 15% fetal bovine serum (FBS), Scf (50 ng/mL), IL3 (10
ng/mL), Flt3 (25 ng/mL), Tpo (10 ng/mL), L-glutamine (2 mM),
sodium pyruvate (1 mM), HEPES buffer (10 mM), penicillin/strep-
tomycin (100 units/mL), β-mercaptoethanol (50 mM). MLL-AF9
leukemia was cultured in a similar media, but without Flt3, or
Tpo. MOLM-13 were grown in  RPMI1640 and  20% FBS; THP-1
in  RPMI1640, 10% FBS, 0.05 mM MetOH; MONOMAC-6 in
RPMI1640, 10% FBS, 2 mM L-glutamine, 2 mM NEAA, 1 mM
sodium pyruvate, 10 ug/mL human insulin; OCI-AML-3 in  
α-MEM and 20% FBS. Fluorescence was detected on a FACS Scan,
Gallios instrument (Beckman Coulter, Brea, CA, USA) or ZE5 Cell
Analyzer (Biorad, Hercules, CA, USA). 
Primary acute myeloid leukemia samples
All cryopreserved AML samples were collected as part of a
study approved by the University of Helsinki after patients pro-
vided informed consent in accordance with the Declaration of
Helsinki. Thawed BM mononuclear cells were suspended in
87.5% RPMI 1640 medium plus 12.5% HS5 stromal cells condi-
tioned media, and supplemented with 10% FBS, L-glutamine (2
mM) and penicillin/streptomycin (100 units/mL). 10,000 cells/well
in 25 mL were plated on 384-well plates containing bexarotene and
ATRA. The cells were incubated with the drugs for 96 h  after
which cell viability was measured with CellTiter-Glo (Promega,
Madison, WI, USA).
Mice
UAS-GFP and Mx1-Cre x Rxraflox/flox x Rxrbflox/flox mice were bred
as previously described.22,23 pIpC treatment was intraperitoneal
injection (IP) with 300 µg/mouse; four doses were given every
other day. Rxra and Rxrb deletion were confirmed by polymerase
chain reaction (PCR). Bexarotene was administrated by oral gav-
age, suspended in sterile α-tocopherol suspension or in corn oil, 1
mg per mouse per day for 5 days/week. Lox-stop-Lox YFP mice
were a gift from Todd Fehniger, Washington University. Dnmt3a-
R878H/FLT3-ITD mouse leukemia cells were generated by Angela
Verdoni and were a gift from Timothy Ley, Washington
University (T Ley, unpublished material, 2019). To generate this line,
hematopoietic cells derived from Dnmt3a R878H mosaic mice
were transduced with an MSCV-FLT3-ITD-IRES-GFP retrovirus,
and transplanted into multiple recipient mice. AML developing in
these mice were confirmed to express the R878H allele by RNA-
seq, with approximately 50% of all reads coming from the mutant
allele (T Ley, personal communication 2019 ). The AML sample (AML-
1) examined in these studies is associated with rapid lethality in
secondary transplants (median 48 days in syngeneic B6 animals)
and an immature myeloid immunophenotype (Cd117+ and partial
expression of Gr-1 and Cd11b) (O di Martino personal observation,
2020). Tet2-KO/FLT3-ITD leukemia cells were a gift from Ross
Levine, Memorial Sloan Kettering Cancer Center. The Washington
University Animal Studies Committee approved all animal exper-
iments.
Study approval
All animal procedures were approved by the Institutional
Animal Care and Use Committee of Washington University. All
cryopreserved human AML samples were collected as part of a
study approved by the University of Helsinki after patients pro-
vided informed consent in accordance with the Declaration of
Helsinki.
Results
RXRA natural ligands are present in MLL-AF9 myeloid
leukemia cells in vivo
RARA and RXRA are preferentially expressed in mature
myeloid cells and this pattern is reflected in a biased
expression in M4/M5 AML where RARA and RXRA
expression correlates with markers of maturation7 (Online
Supplementary Figure S1). Therefore, we hypothesized that
the availability of natural retinoids in hematopoietic
malignancies might also be myeloid biased. 
We evaluated in vivo retinoid ligand availability using a
retroviral model of myelomonocytic leukemia and a
reporter assay we had previously characterized.14,22 
UAS-GFP bone marrow (BM) cells first were transduced
with a retrovirus expressing MLL-AF9 and transplanted
into sublethally irradiated recipient mice (see Figure 1A).
Once leukemia emerged (i.e., UAS-GFP x MLL-AF9),
these cells were transduced with a second retrovirus
(MSCV-Flag-Gal4 DBD-RXRA LBD-IRES-mCherry) and
subsequently transplanted into sublethally irradiated
recipients. Using this strategy, leukemia cells with active,
natural RXRA ligands express GFP (Online Supplementary
Figure S2A and B). Ex vivo, the reporter was sensitive to
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Figure 1. Retinoid X receptors (RXR) natural ligands are present in MLL-AF9 myeloid leukemia in vivo. (A) Schema for bone marrow (BM) transplant procedure. Kit+
cells isolated from the BM of UAS-GFP mice using magnetic-activated cell sorting (MACS) were transduced with MSCV-MLL-AF9, MSCV-Notch1 or MSCV-TLS-ERG retro-
viruses and then injected into sublethally irradiated recipient mice. When leukemia emerged, recipient mice were sacrificed and their leukemic cells harvested.
Leukemia cells were transduced with MCSV-Flag-Gal4-RXRA-IRES-mCherry (Gal4-RXRA), MSCV-Flag-Gal4-RXRA-∆AF2-IRES-mCherry (Gal4-RXRA-DAF2), or MSCV-
Flag-Gal4-RARA-IRES-mCherry (Gal4-RARA) and then injected into sublethally irradiated recipient mice. After leukemia engraftment, leukemia cells were harvested
and the ratio of mCherry+GFP+ versus total mCherry+ cells was evaluated by flow cytometry. (B and C) Representative data showing GFP and mCherry intensity in
MLL-AF9 leukemia cells. (D) Representative GFP and mCherry expression in mice transplanted with MLL-AF9-derived leukemic cells transduced with Gal4-RXRA and
treated with Targretin (bexarotene, 50 mg/kg) by oral gavage administration for 2 days. (E) Combined results from mice transplanted with MLL-AF9-derived leukemia
transduced with Gal4-RXRA (circles; n=5 recipient mice) or RXRA-DAF2 (squares; n=3 recipient mice). (F) Combined results from mice transplanted with MLL-AF9-
derived leukemia cells transduced with Gal4-RXRA and gavaged with bexarotene (Targretin) (squares; n=4 recipient mice) or water (vehicle) (circles; n=4 recipient
mice). (G) Representative GFP and mCherry intensity in MLL-AF9-derived leukemia cells transduced with Gal4-RARA and transplanted into recipient mice (n=3 recip-
ient mice). (H and I) Representative GFP and mCherry intensity in leukemia cells derived with MSCV-Notch1 (n=5 recipient mice) or MSCV-TLS-ERG (n=4 recipient
mice) retroviruses, transduced with Gal4-RXRA, and transplanted into recipient mice. t-test with Welch’s correction.
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low nM concentrations of retinoids and exhibited speci-
ficity between RARA and RXRA ligands (Online
Supplementary Figure S2D-F). Although the RXRA LBD is
used in this assay, the ligand-binding pocket is highly con-
served between RXRA, RXRB, and RXRG, and no RXR
subtype-specific compounds have yet been identified,
suggesting that natural ligands that activate RXRA are
likely to cross-react with RXRB and RXRG.25 We noted the
presence of mCherry+GFP+ cells in both BM and spleen
from multiple mice transplanted using three different pri-
mary MLL-AF9 leukemias and engrafted into a total of
five different recipients (Figure 1B and E). As a negative
control, we transduced UAS-GFP x MLL-AF9 leukemia
cells with a retrovirus expressing  Gal4-RXRA-DAF2,
Tumor suppressor activity of RXR in AML
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Figure 2. Retinoid X receptors (RXR) act as tumor suppressors in mouse MLL-AF9 leukemias. (A) Schema for leukemia transplant procedure. Rxraflox/flox x Rxrbflox/flox
x Mx-Cre bone marrow (BM) cells were collected from the donor mice and transduced as indicated and injected into sublethally irradiated recipient mice. Upon
leukemia engraftment, the proportion of Rxra and Rxrb deletion was assessed by polymerase chain reaction (PCR). (B) PCR results from representative donor BM
cells with “Flox” indicating the retained and “∆” the deleted allele. (C-E) PCR analysis of Rxra and Rxrb alleles from leukemias that emerged from individual mice.
Bar graphs display the quantified percentage of deleted alleles in each unique leukemia. ImageJ software was used for quantification analysis. (F) Kaplan-Meier sur-
vival curve of mice injected with Rxraflox/flox x Rxrbflox/flox x Mx-Cre MLL-AF9 leukemic cells (RXR-KO) or Rxraflox/flox x Rxrbflox/flox MLL-AF9 leukemic cells (RXR-flox). Each
cohort consisted of  five mice. Indicated cohorts were treated with three doses of pIpC on days 5-10 (solid lines). (G) Schema for BM transplant procedure of Lox-
stop-Lox-YFP x Mx-Cre mice and YFP evaluation of the hematopoietic cell. Kit+ BM cells from Lox-stop-Lox-YFP x Mx-Cre donor mice were harvested (n=3 donor mice)
and transduced with MSCV-MLL-AF9 retrovirus, then injected into sublethally irradiated recipient mice (n=7 recipient mice). The percentage of yellow fluorescent
protein (YFP) was quantified by flow cytometry in BM cells before transduction and after leukemia emerged. Each line represents results from an individual recipient
mouse.
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which contains a deletion of the RXRA C-terminal helix
12 (AF2 domain); this mutation is able to bind to RXR lig-
ands, but does not transactivate the reporter (Figure 1C
and E, and Online Supplementary Figure S2C).14
In vivo, a significative proportion of cells remained
mCherry+GFP– (Figure 1B). To determine whether RXRA
transactivation could be further stimulated, leukemic
RXRA reporter mice were orally gavaged for 2 days with
50 mg/kg bexarotene using a clinical formulation with
improved solubility (Targretin). Bexarotene is a pan-RXR
agonist and results were compared with vehicle control
(water). We observed that bexarotene treatment further
augmented RXRA-dependent GFP expression (Figure 1D
and F).  In contrast, we did not observe evidence of natural
O. di Martino et al.
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Figure 3. Pharmacologic targeting of natural retinoic acid receptor (RAR)A and retinoid X receptor (RXR)A ligands blocks MLL-AF9 proliferation in vitro. (A) MLL-
AF9 leukemia cells derived from UAS-GFP bone marrow (BM) and transduced with MSCV-Flag-Gal4-RXRA-IRES-mCherry retrovirus (MLL-AF9 Gal4-RXRA cells) were
treated as indicated, replated after 48 hours (h), and total viable cells in 50 mL assessed in duplicate after 96 total h of treatment at indicated doses. (B) MLL-AF9
RXR-flox (wild-type, WT) or RXR-KO (Rxra/Rxrb deficient) leukemia cells (see Figure 2) were treated with all-trans retinoic acid (ATRA) and bexarotene for 96 total h
and the synergy was calculated by SynergyFinder software24 using three different mathematical calculators for synergy versus additive effects (Zip, Bliss, and HAS).
In these calculations, results >1 suggest mathematical synergy, although larger values are typically required for biologically relevant synergy. (C) MLL-AF9 Gal4-RXRA
cells were treated as indicated, replated after 48 h, and total viable cells in 50 mL were assessed in duplicate after 96 total h of treatment. (D-F) MLL-AF9 leukemia
cells were treated as indicated, replated after 48 h, and total viable cells in 50 mL assessed in duplicate after 96 h of total treatment. (G) Rxra/Rxrb deficient MLL-
AF9 leukemia cells (RXR-KO) were transduced with retrovirus encoding MSCV-RXRA (full length)-IRES-mCherry or retrovirus with indicated RXRA mutations.
Mutations and published mutation effects are indicated. 24 h after retroviral transduction, cells were treated in triplicate with 50 nM ATRA/bexarotene, and the pro-
portion of mCherry+ cells was assessed relative to untreated control population after 72 h. **P<0.01, ***P<0.001, t-test with Welch’s correction relative to control. 
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Figure 4. Differentiation and apoptosis induced by all-trans retinoic acid (ATRA)/bexarotene. (A-D) Colony forming units (CFU) in methylcellulose per 2,000 MLL-AF9
leukemia cells treated as indicated and assessed in triplicate. (E) Photographs of MLL-AF9 colonies treated as indicated for 7 days. (F) Cytospin preparation of 
MLL-AF9 leukemia cells treated with or without ATRA and bexarotene for 96 hours (h) stained with Wright-Giemsa. (G) Cytospin preparation of MLL-AF9 leukemia
cells that remains after treatment with ATRA/bexarotene and stained with Wright-Giemsa. (H) Cell division analysis of MLL-AF9 leukemia. On day 0, cells were stained
with FxCycle Violet, and retained dye was assessed at indicated time points by flow cytometry. (I) Annexin V staining of MLL-AF9 leukemia cells after 24, 48, 72, 96,
and 120 h of ATRA and bexarotene treatment in triplicate. (J-L) Relative activity of caspases 3/7, 9, and 8 in MLL-AF9 leukemia cells after 48 h of ATRA and
bexarotene treatment in triplicate. *P<0.05, **P<0.01, ***P<0.001, t-test with Welch’s correction relative to control.
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Figure 5. Interaction of co-repressors NCOR and SMRT with natural retinoic acid receptor (RAR)A : retinoid X receptor (RXR)A heterodimers. (A) Mammalian two-
hybrid assay schema. 293T cells co-transfected with plasmids encoding the reporter: UAS-GFP; “bait”: Gal4-RXRA or Gal4-RARA; and “prey”: VP16-SMRT or 
VP16-NCOR. The percentage of GFP+ cells was assessed 48 hours (h) after transfection by flow cytometry in triplicate. A vector encoding Gal4-VP16 fusion was used
as a positive control. (B) Reversely, 293T cells were co-transfected with plasmids encoding the reporter: UAS-GFP; “bait”: Gal4-SMRT; and “prey”: VP16-RARA and/or
VP16-RXRA. Cells were treated with increasing concentrations of all-trans retinoic acid (ATRA) and bexarotene (0, 100 nM and 1 mM) in triplicate. The percentage of
GFP+ cells was assessed 48 h after transfection by flow cytometry. (C) 293T cells were co-transfected with plasmids encoding the reporter: UAS-GFP; “bait”: 
Gal4-NCOR; and “prey”: VP16-RARA and/or VP16-RXRA. Cells were treated with ATRA and bexarotene (1 mM) in triplicate. The percentage of GFP+ cells was assessed
48 h after transfection by flow cytometry. (D and E) MLL-AF9 leukemia cells derived from UAS-GFP bone marrow and transduced with MSCV-Flag-Gal4-RXRA-IRES-
mCherry retrovirus (MLL-AF9 Gal4-RXRA cells) or MSCV-Flag-Gal4-RARA-IRES-mCherry retrovirus (MLL-AF9 Gal4-RARA cells)  were treated as indicated, replated and
total viable cells in 50 mL assessed after 96 total h of treatment in duplicate. (F) MLL-AF9 cells were treated as indicated, replated and total viable cells in 50 mL
assessed after 96 total h of treatment in duplicate. (G) 293T cells were co-transfected with plasmids encoding the reporter: UAS-GFP; “bait”: Gal4-NCOR or Gal4-
SMRT; and “prey”: VP16-RARA and/or VP16-RXRA. Cells were treated with ATRA, bexarotene, and CW103-4 as indicated in triplicate. The percentage of GFP+ cells
was assessed 48 h after transfection by flow cytometry. *P<0.05, ***P<0.001, t-test with Welch’s correction.
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RARA ligands following transplantation of UAS-GFP x
MLL-AF9 leukemia cells transduced with Gal4-RARA
(Figure 1G), suggesting the absence of RARA ligands, in
MLL-AF9 leukemia cells in vivo. 
To determine whether natural RXRA ligands were pres-
ent in other forms of murine leukemia, we repeated these
studies in leukemias derived using activated Notch1 (T-cell
leukemia)26 and TLS-ERG (erythroleukemia).27 In neither
was the presence of mCherry+GFP+ cells observed (Figure
1H and I). 
RXR acts as tumor suppressors in mouse MLL-AF9
leukemias
Given the presence of natural RXRA ligands in MLL-
AF9 leukemia, we sought to determine whether activated
endogenous mouse Rxrs contribute to leukemic growth in
vivo. We transduced Mx-Cre x Rxraflox/flox x Rxrbflox/flox BM
cells with MLL-AF9 retrovirus, transplanted these into
sublethally irradiated recipient mice, and derived subse-
quent leukemias (see Figure 2A). Of note, Rxrg expression
is low to absent in hematopoietic cells (Online
Supplementary Figure S1G).28 We performed our initial
retroviral transduction and transplantation in the absence
of polyinosinic:polycytidylic acid (pIpC)  treatment.
However, low levels of native interferons induced Mx-Cre
activity in a subset of cells, and a small proportion of BM
cells exhibited Rxra and Rxrb deletion prior to transduction
and transplantation (Figure 2B).23 Unexpectedly, all MLL-
AF9-derived primary leukemias emerged with almost
100% deletion of both Rxra and Rxrb alleles even in the
absence of any pIpC injections (Figure 2C), suggesting a
strong positive selection for the D/D (deleted) alleles. In
Tumor suppressor activity of RXR in AML
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Figure 6. All-trans retinoic acid (ATRA)/bexarotene in different leukemia cell lines and in human acute myeloid leukemia (AML) ex vivo. (A and B) Colony forming
units (CFU) in methylcellulose per 2,000 Dnmt3a R878H/FLT3-ITD and Tet2-KO/FLT3-ITD leukemia cells treated as indicated for 7 days in duplicate. (C) Zip synergy
score of ATRA and bexarotene interactions calculated by SynergyFinder.24 (D and E) Cell viability of primary human AML leukemia samples treated for 96 hours ex
vivo with ATRA and bexarotene at indicated concentrations assessed in duplicate by CellTiter-Glo (CTG). Dx: sample acquired at initial diagnosis; R: sample acquired
at relapse. *P<0.05, **P<0.01, t-test relative to control.
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contrast, repeat experiments deriving Notch1 T-cell
leukemia and TLS-ERG erythroleukemias showed near
complete retention of Rxraflox/flox and Rxrbflox/flox alleles (Figure
2D and E). We performed secondary transplantation of
MLL-AF9 leukemia cells derived from Mx-Cre x Rxraflox/flox
x Rxrbflox/flox and from Rxraflox/flox x Rxrbflox/flox mice using 1x106
leukemia cells per recipient. Because these tumors were
transplanted immediately, we were unaware of their dele-
tion status and separately treated cohorts of mice with
pIpC or control intending to determine whether the delet-
ed allele augmented growth. We subsequently noted that
primary tumors derived from Mx-Cre+ mice already car-
ried deleted alleles and that these Rxra/Rxrb null (RXR-KO)
leukemias resulted in shorter latency than tumors derived
from Mx-Cre– mice, and that further stimulation by pIpC
did not impact survival (Figure 2F). This suggests that
RXR-KO leukemia cells grow more quickly in vivo than
their wild-type counterparts, and could, therefore, have
outgrown the wild-type populations during the primary
transplantations. To exclude the possibility that MLL-AF9
leukemogenesis or hematopoietic transplantation could
non-specifically activate Mx-Cre and induce deletion of
the Rxr alleles, we crossed Mx-Cremice with Lox-stop-Lox-
YFP reporter mice and derived seven independent 
MLL-AF9 leukemias using three individual donors. The
leukemia cells that emerged were not associated with
increased YFP expression, suggesting that Mx-Cre activa-
tion does not routinely occur following viral MLL-AF9
leukemogenesis and transplantation (Figure 2G). 
Pharmacologic targeting RXRA and RARA in vitro
In vitro, bexarotene exerted dose-dependent growth
inhibition in UAS-GFP x MLL-AF9 x Gal4-RXRA leukemia
cells, although the effect was modest (2-4 fold) (Figure 3A,
red line). Because Rxrs act as heterodimers with other
orphan receptors, we screened for interactions with addi-
tional ligands. The combination of bexarotene with either
ATRA or tamibarotene (an RARA-specific agonist) lead to
profound, dose-dependent growth inhibition while single-
agent RARA ligands resulted in only modest (2-4 fold)
growth inhibition (Figure 3A, blue and brown lines).
Response and synergy were absent in RXR-KO MLL-AF9
leukemia cells (Figure 3B). The effect of ATRA on
leukemic growth inhibition reached a plateau at 60-100
nM, whereas increasing concentrations of bexarotene
were associated with increasing growth reduction up to 
1 mM (Figure 3C). After 5 days of retinoids, we noted the
proportion of GFP+ cells and the GFP median fluorescence
intensity (MFI) was significantly reduced (Online
Supplementary Figure S3A and B), suggesting that the most
RXR responsive cells experienced the greatest negative
selection by retinoid treatment. 
We tested a series of additional nuclear receptor ligands
for anti-leukemic activity. A broad range of RXR ligands
cooperated with ATRA to induce anti-leukemic activity
and again displayed only modest single-agent activity
(Online Supplementary Figure S4A and B). The RARA-spe-
cific agonist BMS753, but not the RARG-specific agonist
BMS961, cooperated with bexarotene to inhibit MLL-AF9
cell growth (Figure 3D and E). RXR weak agonists and
antagonists (LG100754 and HX531) were insufficient to
cooperate with ATRA or tamibarotene (RARA specific
agonist) and the pan-RAR inverse agonist BMS493 inhib-
ited the effect of combination ATRA and bexarotene
(Online Supplementary Figure S4C and D). Finally, the
PPARA agonist GW7647, PPARG agonist pioglitazone,
and the LXR agonist GW3965 had modest effects with
bexarotene (Figure 3F and Online Supplementary Figure S4E
and F). 
RXRA domains required for retinoid sensitivity
To map the structural domains of RXRA required for
anti-leukemic activity, we retrovirally re-expressed RXRA
in RXR-KO MLL-AF9 leukemia cells (Figure 3G). mCherry
expression identified transduced cells. A series of RXRA
deletions and mutations were generated and the position
of the LBD mutations are highlighted within an available
RXRA crystal structure (Protein Database: 4K4J) (Online
Supplementary Figure S5A and B). The expression of the
RXRA mutants was confirmed by western blot (Online
Supplementary Figure S5C). In cells transduced with full-
length RXRA, bexarotene and ATRA induced a strong
decrease in the proportion of mCherry+ cells after 48 h
(Figure 3G), consistent with a strong retinoid sensitivity
among cells expressing wild-type RXRA. We found that
mutants lacking the AF1, DBD, or AF2 domain and muta-
tions reported to: disrupt the DNA binding zinc finger
(E153G/G154S),29 reduce co-activator binding
(L276A/V280A),30 or  abrogate ligand binding
(R316A/L326A),31 were unresponsive to retinoids (Figure
3G). Additional mutations reported to: reduce co-activator
binding (E453A, V298A/L301A),32 reduce intracellular traf-
ficking of RXRA (S260A),33 obstruct the heterodimer inter-
face (Y402A, R426A)34 or reduce co-repressor binding to
RXRA (K440E),32 largely retained sensitivity to retinoids
(Figure 3G). These data demonstrate the necessity of spe-
cific, functional RXRA domains (AF1, DBD, and AF2), as
well as RXRA co-activator-interacting moieties for the
activity of the RARA:RXRA heterodimer.
Maturation and apoptosis induced by ATRA/bexarotene
Retinoids have been associated with myeloid matura-
tion programs.35-38 We observed that different culture con-
ditions influenced the effect of retinoid-induced matura-
tion and apoptosis in MLL-AF9 leukemia. When grown in
methylcellulose, combination ATRA/bexarotene reduced
colony-forming capacity in a dose-dependent manner
(Figure 4A); these effects were associated with changes in
the number of colonies, the size of the colonies (smaller),
colony morphology (diffusion of cell clustering), and cellu-
lar cytomorphology (acquisition of vacuoles), consistent
with loss of self-renewal and maturation (Figure A-F).
Again, these phenotypes were absent in RXR-KO
leukemia cells and single-agent retinoids resulted in mod-
est effects. However, when MLL-AF9 leukemia cells were
grown in liquid culture, retinoid combinations did not
induce cytomorphologic changes or cell cycle exit, but
rather, they induced time- and dose-dependent apoptosis
and activation of intrinsic caspase pathways (Caspases 3/7
and 9) (Figure 4G-L). 
Co-repressor binding to RARA:RXRA heterodimers
The synergy observed between ATRA and bexarotene
suggests different effects within the RARA:RXRA het-
erodimer. In the absence of retinoids, the RARA:RXRA
heterodimer binds to co-repressors such as the nuclear
receptor co-repressor (NCOR1) and silencing mediator of
retinoic acid and thyroid hormone receptor (SMRT, aka
NCOR2).39-42 Using a mammalian two-hybrid assay in
293T cells,43 we noted that RARA resulted in greater tran-
O. di Martino et al.
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scriptional activity with either co-repressor (SMRT) versus
RXRA, suggesting a stronger affinity of RARA to co-
repressors than RXRA (Figure 5A). Similarly, when the
bait and prey strategy was reversed (Figure 5B), ATRA led
to greater reporter inhibition than bexarotene, with as
great an effect as the combination of ATRA and
bexarotene (Figure 5B). Similar results were noted using
NCOR as bait (Figure 5C), suggesting that co-repressor
interactions with RARA:RXRA heterodimers are dominat-
ed by interactions with RARA. 
A bexarotene derivative (CW103-4) had been identified
with potential dual RARA/RXRA activity.44-46 CW103-4
has improved murine pharmacokinetics compared with
bexarotene (peak plasma concentration of 152,955.83 vs.
18,633.33 ng/mL and area under the curve of 51,531 vs.
8,523 ng/mL).43 However, this is associated with a 5-fold
increase in triglycerides 24 h after treatment,43 making it
an interesting tool compound, but not an obvious clinical
therapy. We assessed this compound to determine
whether its dual-affinity might provide single-agent activ-
ity in vitro. Indeed, CW103-4 exhibited dual RARA and
RXRA activation in UAS-GFP x MLL-AF9 leukemia cells,
and was capable of ATRA-independent anti-leukemic
activity (Figure 5D-F and Online Supplementary Figure S6A-
D). Specifically, CW103-4 induced proliferative capacity
reduction and apoptosis mediated by caspases 3/7 activa-
tion (Online Supplementary Figure S6A-D). Interestingly,
CW103-4 also induced consistent single-agent co-repres-
sor release (Figure 5G). To determine whether these
effects might occur through LXRs or PPARD, we assessed
reporter activation and found no evidence of cross-reactiv-
ity with these receptors (Online Supplementary Figure S6E-
G). These results suggest that single-agent bexarotene is
ineffective to induce co-repressor release from the
RARA:RXRA heterodimer, and that co-repressor release
results primarily from RARA activation, providing an
explanation for the anti-leukemic combination synergy
(Figure 3A and B).
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Figure 7. Concurrent all-trans retinoic acid (ATRA)/bexarotene treatment reduces MLL-AF9 leukemia burden in vivo. (A) Schema for leukemia transplant procedure
and in vivo treatment. Sublethally irradiated FVB mice were transplanted with 0.5x106 MLL-AF9 leukemia cells. Ten days later the mice were divided in four different
cohorts and treated with 21-day release ATRA pellets. 5 mg: n=5 (~0.23 mg/day), 10 mg: n=5 (~0.5 mg/day), and 25 mg: n=8 (~1.2 mg/day). One day after pellet
implantation, bexarotene (50 mg/kg) was delivered by oral gavage as indicated. A control cohort was implanted with placebo pellets and treated with the vehicle gav-
age (n=12). IV: intravenous. (B) The mice were sacrificed 21 days from pellet implantation and the spleen weight analyzed. (C) Kaplan-Meier survival curve analysis
of mice transplanted with MLL-AF9 cells and treated as indicated in (A). (D) Schema for leukemia transplant procedure and mice treatment. FVB mice were trans-
planted with 1.5x106 MLL-AF9 leukemia cells by intraperitoneal (IP) injection. Five days later the mice were divided in four different cohorts and implanted with 21-
day release ATRA pellets 25 mg (~1.2 mg/day) or placebo pellets. One day after pellet implantation, bexarotene (Targretin, 50 mg/kg) was delivered by oral gavage
as indicated. (E) Kaplan-Meier survival curve analysis of mice transplanted with MLL-AF9 cells and treated as indicated in (E). *P<0.05, **P<0.01, ***P<0.001, 
t-test. 
 A                                                                                                                  B
 D                                                                                 E
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ATRA/bexarotene responses in diverse acute myeloid
leukemias
To determine whether retinoid combination efficacy
was limited to MLL-AF9 models or might extend to other
leukemias, we examined the effect of combination
ATRA/bexarotene on the proliferative capacity of two
additional primary murine AML. The first was derived in
the Timothy Ley lab using a Dnmt3a R878H knock-in
allele and BM cells transduced with MSCV-FLT3-ITD
virus containing GFP (Dnmt3a R878H/FLT3-IT (T Ley,
unpublished observations, 2019). The second was derived in
the Ross Levine lab using germline Tet2 deficiency crossed
with a germline FLT3-ITD allele (Tet2-KO x FLT3-ITD).47
Both primary mouse leukemias could be grown transient-
ly in methylcellulose, and we observed anti-leukemic
activity of combination retinoids, with limited effects by
single agents (Figure 6A and B). We examined cell growth
of several human AML cell lines and primary human AML
following ATRA/bexarotene treatment, noting low nM
IC50 combination ATRA/bexarotene in THP1, Monomac6,
OCI-AML-3, and MOLM13 (1.3±1.2, 19.2±1.7, 5.0±1.1,
and 15.8±1.2, respectively), with evidence of synergy in
THP1 and MOLM13, both of which contain MLL translo-
cations (Figure 6C). Slightly higher IC50 values were
observed for CW103-4 (8±1.1, 43±1.2, 20±1.1, and
24±1.4, respectively). We also assessed retinoid responses
in a series of primary AML samples collected at diagnosis
or relapse and noted evidence of response and modest
synergy in samples with MLL translocations (KI_1, 7346,
and 5184) (Figure 6D and E). 
ATRA/bexarotene activity in vivo 
To determine whether retinoid combinations could be
transitioned into in vivo activity, we first assessed the
potential tolerability of the combination on normal
hematopoiesis. Two cohorts of 5 wild-type mice were
treated with ATRA/bexarotene by oral gavage or vehicle
control. No differences were noted in the peripheral blood
counts after 3 weeks of treatment (Online Supplementary
Figure S7A-E), suggesting tolerance of the combination by
normal hematopoiesis. 
Subsequently, we tested the effect of combination
retinoids on MLL-AF9 leukemia in vivo. In our first studies,
we engrafted MLL-AF9 leukemia cells using sublethal irra-
diation and we treated mice with slow-release
ATRA/bexarotene pellets implanted subcutaneously.
However, this lead to wound dehiscence and loss of the
pellets (data not shown). Second, four cohorts of mice were
treated with 21 days ATRA release pellets (placebo, 5 mg,
10 mg, and 25 mg, which provide an average of 0.23 mg,
0.5 mg, and 1.2 mg/day, respectively). The day after pellet
implantation, all ATRA cohorts received bexarotene by
oral gavage (in α-tocopherol, 50 mg/kg, which is reported
to be better tolerated as a vehicle than corn oil during seri-
al administration)48 (Figure 7A). However, tolerance of the
combination by the mice was quite poor, as they exhibit-
ed reduced activity the day after gavage, ruffled fur,
weight loss, and poor wound healing, and bexarotene
could be administered only every other day (qod) (Online
Supplementary Figure S7F). After 21 days from pellet
implantation, the mice were sacrificed and the spleen
weight was analyzed. This end-point was designed to iso-
late leukemic growth from confounding factors of toxicity.
We observed a significant dose-dependent effect of com-
bination retinoid treatment in reducing the tumor burden
(spleen weight) of treated mice compared to the control
cohort (Figure 7B). Of note, the in vivo steady-state serum
concentration of ATRA resulting from 10 mg 21-day
release pellets is reported as 100-220 nM,49 and the 5 mg
pellets did not provide a sufficient dose to inhibit leukemic
growth.
Third, we suspected that some of the toxicity might be
due to retinoid-induced radiation recall, a known compli-
cation of retinoids,50,51 and tolerability might be improved
using a micronized formula of bexarotene found in the
clinical Targretin formulation.52 We found that MLL-AF9
leukemia cells engrafted consistently following IP injec-
tion without irradiation conditioning, with improved fur
ruffling, improved wound healing, and no weight loss
(Online Supplementary Figure S7G). However, the mice
again exhibited reduced activity the day after gavage and
administration was again reduced to qod due to tolerabil-
ity. Despite this, the combination of ATRA/bexarotene
was associated with improved survival (Figure 7D and E).
This study was repeated a fourth time with similar mod-
est, but significant, improvement in survival and tolerabil-
ity issues that persisted (data not shown). Thus, retinoid
delivery to mice in the context of leukemic models
remains a challenge, but is still associated with a statistical
and reproducible survival advantage, although modest. 
Discussion
Retinoid therapy has transformed the treatment of
APL.16,17 Retinoids have been explored in different clinical
trials in non-APL, and their action has repeatedly been
shown, although never to the extent seen in APL.18
We previously found that natural RXRA ligands are
present in mouse hematopoietic cells in vivo, that they are
biased toward myeloid cells and dynamically regulated
under myeloid stress (e.g., GCSF treatment).14 Consistent
with those findings, in this study we found also that a
malignant myeloid stressor (MLL-AF9 transformation)
was associated with natural in vivo RXRA ligands. In vivo
natural RXRA ligands resulted in incomplete reporter acti-
vation, and pharmacologic doses of ligands could activate
the reporter further under both basal conditions14 and
leukemic stress (Figure 1). In contrast to these RXRA
results, we have been unable to detect natural RARA lig-
ands (Figure 1G).14,22
We found that MLL-AF9 cells that carried deleted Rxra
and Rxrb alleles had a competitive advantage during MLL-
AF9 leukemogenesis (Figure 2C and F). Whereas Notch-
derived T-cell leukemias and TLS-ERG-derived ery-
throleukemia were not associated with in vivo natural
RXRA ligands, and also were  not associated with a com-
petitive advantage among cells with Rxra or Rxrb deletion
(Figures 1 and 2). Thus, the presence versus absence of
active natural ligands may determine whether RXR exert
tumor suppressor activity.
RXR form heterodimers with a wide range of orphan
nuclear receptors. Other groups have reported co-opera-
tivity of RXR ligands with either RARA ligands37 or LXR
ligands.53 MLL-AF9 leukemia cells appeared most sensitive
to the combination of RARA and RXR ligands (Figure 3).
Culture conditions influenced retinoid responses, and we
observed that combinations of retinoids induced either
maturation or apoptosis depending on whether the
leukemia cells were grown in methylcellulose or liquid
O. di Martino et al.
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culture (Figure 4). The relevant cell signals that influence
retinoid responses in these two settings still have to be
defined.
The synergy of ATRA and bexarotene can be under-
stood within the context of co-repressor interactions with
the RARA:RXRA heterodimer. Other studies of the
RARA:RXRA heterodimer identified a subordinate role for
RXR.32,39,41,42 Consistent with those results, mammalian
two-hybrid assays demonstrated that RARA bound more
effectively to co-repressors, that ATRA was more efficient
than bexarotene at releasing co-repressors from
RARA:RXRA, and that these limitations could be over-
come using a bexarotene-derivative compound with dual
RARA/RXRA activity (CW103-4) (Figure 5). Thus, the
ATRA-dependent release of co-repressor from the
RARA:RXRA heterodimer may account for the synergy
observed between ATRA and bexarotene. 
Within the RARA:RXRA heterodimer, specific RXRA
domains appear necessary for anti-leukemic effects,
including the AF1, DBD, and AF2, as well as amino acids
responsible for ligand-binding and co-activator recruit-
ment (Figure 3G). Thus, although ligand activation of RXR
may be subordinate to RAR, RXR play an active, not a
passive role in anti-leukemic response to ligands. 
Other studies have suggested that biomarkers may
identify subsets of retinoid-sensitive patients.54,55 We note
that expression of RARA and RXRA are co-ordinately reg-
ulated in AML with highest expression in M4/M5-FAB
AML (Online Supplementary Figure S1). Cell lines and pri-
mary AML samples suggest that combination retinoids
may be active in leukemias beyond the mouse MLL-AF9
model and a potential bias in sensitivity within this group
of patients (Figure 6). Larger studies will be required to
accurately determine the specificity and sensitivity of
these biomarkers as predictors of retinoid responses in
non-APL AML. We have established an on-going ex vivo
biomarker study of primary AML samples (clinicaltrials.gov
identifier: NCT04263181) to further address this issue.
Although both ATRA and bexarotene are well-tolerat-
ed orally-available compounds, approved by the US
Food and Drug Administration, we found it difficult to
provide mice with a sufficient dose to enable us to
observe any big effects (Figure 7). Both oral ATRA and
bexarotene are poorly soluble, have short serum half-
lives (1 and 7 h, respectively), and their BM concentra-
tions may be locally reduced by stroma expression of
P450 enzymes.56 Given the short serum half-life of
bexarotene, our administration of bexarotene (given
every other day) is likely associated with a suboptimal
area under the curve and incomplete receptor activation
in vivo. Although ATRA is highly active against APL,
administration and in vivo activity of ATRA in mouse
models of APL have been surprisingly modest. For exam-
ple, across multiple mouse models, ATRA improved
median survival in secondary transplants: 53 days versus
31 days,57 35 versus 25 days,58 approximately 90 days ver-
sus approximately 50 days,59 approximately 75 days 
versus approximately 35 days,60 approximately 45 days 
versus approximately 35 days,61 and approximately 130
days versus approximately 85 days.49 In contrast,
Westervelt et al. found that a liposomal formulation of
ATRA (that is now no longer commercially available)
resulted in much higher levels of ATRA in mice than
ATRA slow-release pellets, and in 88% long-term sur-
vival. Therefore, additional chemical or formulaic modi-
fications may be required to optimize in vivo retinoids as
anti-leukemic therapeutics, and the combination of free
acid ATRA and bexarotene is not sufficient to overcome
these limitations.
In summary, we find evidence of natural RXRA, but not
RARA ligands in myelomonocytic MLL-AF9 mouse
leukemia in vivo where the concurrent presence of recep-
tors and active ligands acts as tumor suppressors. RARA
and RXRA are co-ordinately expressed in myelomonocyt-
ic leukemias, and optimal retinoid activation appears to
require concurrent activation of both elements in the
RARA:RXRA heterodimer, providing a further step
toward improved retinoid therapeutics in AML.  
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